Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Biological Chemistry

DNA Assay Predicts Cancer Relapse

Diagnostics: Tracking mutations in circulating tumor DNA predicts disease recurrence months before conventional scans

by Celia Henry Arnaud
August 31, 2015 | APPEARED IN VOLUME 93, ISSUE 34

In some cases of early-stage breast cancer, the seeds of metastasis have already been planted even when treatment seems successful. A method for predicting which women will relapse could help in designing clinical trials for more effective treatments. A team led by Nicholas C. Turner of Royal Marsden Hospital and the Institute of Cancer Research, both in London, has found that it can predict relapse in early-stage breast cancer by tracking mutations in circulating tumor DNA (ctDNA) (Sci. Transl. Med. 2015, DOI: 10.1126/scitranslmed.aab0021). The researchers used digital polymerase chain reaction assays to quantify specific mutations in ctDNA in plasma samples from 55 women. For each patient, they obtained plasma samples before and after surgery and at six-month intervals for two years or until relapse. They also collected samples from most patients two to four weeks after surgery and used them to determine the benefit of analysis at a single time point. Serial sampling was better for predicting relapse than single-point analysis. The study shows that measurement of ctDNA can predict relapse months before it is detectable with conventional scans.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment